Can-Fite BioPharma ( (CANF) ) just unveiled an update.
Namodenoson’s Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Candidate in the Growing Obesity Treatment Market ...
Namodenoson’s Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Candidate in the Growing Obesity Treatment Market ...
Namodenoson's oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can- ...
Namodenoson Provided Clinical Stabilization as a Potential Bridge to Transplant in Advanced Liver Failure Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: ...
Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs ...
Can-Fite BioPharma Ltd. (NYSE American:CANF) announced Monday that it will hold a Special General Meeting of Shareholders on March 3, 2026, at its offices in Ramat Gan, Israel. The meeting will ...
Can Fin Homes’ (CANF) PAT for 3QFY26 grew ~25% YoY to INR2.6b (in line). NII grew 22% YoY to ~INR4.2b (in line). Fee and other income stood at ~INR97m (PY: INR58m). Opex rose ~35% YoY to INR799m (in ...
Ramat Gan, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small ...
Click the link below to download a spreadsheet with an example Revenue calculation for Can Fite Biopharma Ltd ADR below: The chart above depicts the distribution of Revenue for companies operating in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results